Victory Capital Management
TCRR

Victory Capital Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Victory Capital Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-74,297
Closed -$74.2K – 2726
2022
Q4 		$74.2K Sell
74,297
-9,945
-12% -$13.4K ﹤0.01% 2402
2022
Q3 		$152K Sell
84,242
-1,585
-2% -$4.6K ﹤0.01% 2404
2022
Q2 		$249K Buy
85,827
+1,035
+1% +$2.55K ﹤0.01% 2284
2022
Q1 		$181K Buy
84,792
+385
+0.5% +$1.21K ﹤0.01% 2423
2021
Q4 		$393K Sell
84,407
-13,006
-13% -$81.3K ﹤0.01% 2288
2021
Q3 		$829K Sell
97,413
-42,327
-30% -$598K ﹤0.01% 1939
2021
Q2 		$2.29M Sell
139,740
-1,091,660
-89% -$22.1M ﹤0.01% 1592
2021
Q1 		$27.2M Buy
1,231,400
+1,022,384
+489% +$27.9M 0.03% 791
2020
Q4 		$6.46M Buy
209,016
+71,251
+52% +$1.8M 0.01% 1178
2020
Q3 		$2.8M Buy
137,765
+54,266
+65% +$953K ﹤0.01% 1345
2020
Q2 		$1.28M Sell
83,499
-84,983
-50% -$980K ﹤0.01% 1609
2020
Q1 		$1.3M Buy
168,482
+82,050
+95% +$1M ﹤0.01% 1760
2019
Q4 		$1.23M Buy
86,432
+73,578
+572% +$1.14M ﹤0.01% 1676
2019
Q3 		$193K Buy
12,854
+1,854
+17% +$28.9K ﹤0.01% 2232
2019
Q2 		$157K Hold
11,000
– – ﹤0.01% 1474
2019
Q1 		$192K Buy
+11,000
New +$195K ﹤0.01% 1578

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Victory Capital Management's TCRR Position: Q1 2023 in Review

Victory Capital Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2023, closing a stake of 74,297 shares — an estimated $74.2K sold.

Victory Capital Management first reported a position in TCRR in Q1 2019 and held it in 16 quarters. The position peaked at $27.2M in Q1 2021. 59 funds tracked by Wall St. Rank hold TCRR as of Q1 2023.

  • Victory Capital Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Victory Capital Management sold 74,297 TCR2 Therapeutics Inc. Common Stock shares in Q1 2023, an estimated $74.2K.
  • Victory Capital Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 16 quarters.
  • Victory Capital Management's TCR2 Therapeutics Inc. Common Stock position peaked at $27.2M in Q1 2021.
  • 59 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2023.

Based on Victory Capital Management's 13F filing for Q1 2023, filed 2 May 2023.